Skip to main content
OpenTrials

Clinical trial condition

Follicular Lymphoma Grade 3B

Explore clinical trials studying Follicular Lymphoma Grade 3B. Study availability and eligibility vary by location and protocol.

10 public trials 5 recruiting studies
Refine in advanced search Browse all conditions

Follicular Lymphoma Grade 3B trial results

Recruiting

SynKIR-310 for Relapsed/Refractory B-NHL

NCT06544265

Conditions
Aggressive B-Cell Non-Hodgkin Lymphoma, B Cell Lymphoma, Blood Protein Disorders, +54 more
Locations
  • Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute Denver, Colorado, United States
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
  • The University of Kansas Cancer Center Fairway, Kansas, United States
  • Rutgers Cancer Institute New Brunswick, New Jersey, United States
View Trial Details
Recruiting

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

NCT05326243

Conditions
Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3A, Follicular Lymphoma Grade 3B, +13 more
Locations
  • National Taiwan University Hospital Taipei, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City, Taiwan
  • Chi Mei Medical Center Tainan, Taiwan
  • Taipei Medical University - Taipei Medical University Hospital Taipei, Taiwan
View Trial Details
Recruiting

Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

NCT05377307

Conditions
Dendritic Cell Sarcoma, Interdigitating, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3A, +16 more
Locations
  • Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung, Taiwan
  • National Taiwan University Hospital Taipei, Taiwan
  • Taipei Veterans General Hospital Taipei, Taiwan
  • Chi Mei Medical Center Tainan, Taiwan
View Trial Details
Not Yet Recruiting

Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment

NCT07476105

Conditions
Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B, Hemic and Lymphatic Diseases, +10 more
Locations
  • Azienda Ospedaliero Universitaria delle Marche - S.O.D. Clinica Ematologica Ancona, Italy
  • A.O.R.N. S. Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico Avellino, Italy
  • I.R.C.C.S. Centro di Riferimento Oncologico - S.O.C. Oncologia medica e dei tumori immuno-correlati Aviano, Italy
  • I.R.C.C.S. Istituto Tumori Giovanni Paolo II - U.O.C. Ematologia Bari, Italy
View all 24 locations
View Trial Details
Active, Not Recruiting

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

NCT06014762

Conditions
DLBCL, DLBCL - Diffuse Large B Cell Lymphoma, DLBCL Arising From Follicular Lymphoma, +21 more
Locations
  • Loma Linda University Cancer Center Loma Linda, California, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • Advent Health Orlando Orlando, Florida, United States
  • Indiana University Indianapolis, Indiana, United States
View all 16 locations
View Trial Details
Active, Not Recruiting

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

NCT06093841

Conditions
Follicular Lymphoma Grade 3B, Hemic and Lymphatic Diseases, High-grade B-cell Lymphoma, +11 more
Locations
  • Sun Yat-sen University Cancer Hospital Guangzhou, Guangdong, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, China
  • Hunan Cancer Hospital Changsha, Hunan, China
View all 13 locations
View Trial Details

Related conditions